Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391545 · ClinicalTrials.gov registry record · Phase 1
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
A Phase 1 study, sponsored by SecuraBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02391545 is a Phase 1 study that was terminated before completion, run by SecuraBio. The registered enrollment target is 55 participants.
The verdict
NCT02391545, a Phase 1 study, was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
Interventions
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02391545
The ClinicalTrials.gov registry entry for NCT02391545 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT02391545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02391545 about?
NCT02391545 is a clinical study titled "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)". A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
What is the current status of trial NCT02391545?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2014-12. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02391545?
The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT02391545?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.